| 24.04 07:00 | Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales |
| 24.04 07:00 | dpa-AFX: EQS-Adhoc: Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales (english) |
| 17.04 14:05 | Annual General Meeting of Kuros Biosciences approves all resolutions |
| 17.04 14:05 | dpa-AFX: EQS-News: Annual General Meeting of Kuros Biosciences approves all resolutions (english) |
| 13.03 07:00 | dpa-AFX: EQS-Adhoc: Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023 (english) |
| 13.03 07:00 | Kuros reports 163% growth in direct MagnetOs -2- |
| 13.03 07:00 | Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023 |
| 08.03 07:00 | dpa-AFX: EQS-News: Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update (english) |
| 08.03 07:00 | Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update |
| 01.02 07:00 | Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference |
| 01.02 07:00 | dpa-AFX: EQS-News: Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference (english) |
| 31.01 07:00 | dpa-AFX: EQS-News: Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand (english) |
| 31.01 07:00 | Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand |
| 04.01 07:00 | Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA |
| 04.01 07:00 | Kuros Biosciences Announces Three Advancements -2- |
| 04.01 07:00 | dpa-AFX: EQS-News: Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA (english) |
| 27.12 17:42 | Aktien Schweiz nach Weihnachtspause etwas leichter |
| 27.12 07:00 | dpa-AFX: EQS-Adhoc: Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA (english) |
| 27.12 07:00 | Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA |
| 27.12 07:00 | Kuros Biosciences Announces Results from Two -2- |
|
|
